Delving into the Latest Updates on Laboratoire Chauvin SAS with Synapse

Overview

This is a multicenter, randomized, parallel group, investigator-masked, non-inferiority study. Approximately 84 subjects will be randomized in a 1:1 ratio.The primary objectives of this investigation are to show that the performance of CBL-102 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-102 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day. The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye at Visit 4 (Day 28 ± 3 days) in ocular surface fluorescein staining score.

Start Date09 Nov 2017

Sponsor / Collaborator

Laboratoire Chauvin SAS

NCT02975102

/ CompletedNot Applicable

A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

The primary objectives of this investigation are to show that the performance of CBL-101 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-101 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day.

Start Date01 Mar 2017

Sponsor / Collaborator

Laboratoire Chauvin SAS

[+1]

100 Clinical Results associated with Laboratoire Chauvin SAS

Login to view more data

0 Patents (Medical) associated with Laboratoire Chauvin SAS

Login to view more data

4

Literatures (Medical) associated with Laboratoire Chauvin SAS

01 Jan 1997·BiomaterialsQ1 · ENGINEERING & TECHNOLOGY

Influence of sterilization processes on poly(ε-caprolactone) nanospheres

Q1 · ENGINEERING & TECHNOLOGY

Article

Author: Devissaguet, J. P. ; Maurin, F. ; Fessi, H. ; Masson, V.

Polymeric vectors and especially poly(epsilon-caprolactone) nanoparticles have already shown promising results in the optimization of the ophthalmic bioavailability of drugs. Any formulation instilled in the eye must be sterile, and preferentially isotonic. Poly(epsilon-caprolactone) nanospheres were thus formulated with Synperonic PE/F68, Synperonic PE/F127, or Cremophor RH40. A tonicity agent, a preservative and, in some cases, a viscosifiant were then added. The pH was finally adjusted to pH 4 or buffered to pH 7. Different sterilization processes were studied to investigate their influence on the physicochemical characteristics of vectors. Autoclaving did not induce any modification on polymer molecular weight or Synperonic nanospheres diameter, but catalysed some reactions with surfactants and tonicity agents. This method could thus be used if the nanosphere excipients are chosen with care. gamma radiation induced preservative degradation and viscosifiant depolymerization. A cross-linking of poly(epsilon-caprolactone) chains was observed, as reflected by a sharp increase of its molecular weight. However, no variation of the mean particle size was detected. Finally, sterile filtration was the only process which ensured the conservation of physicochemical integrity of nanospheres. This process was successfully applied on non-viscosified vectors with a sufficiently small diameter.

Arzneimittel-Forschung

2-(2-Hydroxy-4-methylphenyl)aminothiazole hydrochloride as a dual inhibitor of cyclooxygenase/lipoxygenase and a free radical scanvenger. 2nd Communication: Anti-inflammatory activity

Author: Muller, A. ; Malet, F. ; De Kozak, Y. ; Bonne, C. ; Giroud, J. P. ; Colin, J. ; Latour, E. ; Tissot, M. ; Faure, J. P.

The topical anti-inflammatory activity of 2-(2-hydroxy-4-methylphenyl)aminothiazole hydrochloride (CBS-113 A), a dual inhibitor of cyclooxygenase/lipoxygenase and a potent free radical scavenger was studied in rats, rabbits, guinea pigs, and mice.When applied in eye drops (0.01-0.1% according the model used), the drug inhibited inflammation in exptl. conjunctivitis and uveitis induced by various procedures (e.g. paracentesis, endotoxin, S-antigen, albumin, Fe²⁺).The compound also inhibited leukocyte infiltration and histamine release when administered locally in the pleural cavity with carrageenan.CBS-113 A could decrease plasma leakage induced by arachidonic acid or platelet-activating factor in skin and airway, resp.However, it was devoid of any activity when administered by the systemic route.The compound appears as a potentially useful anti-inflammatory drug, in particular in ophthalmol. and as an alternative to glucocorticoids, since it does not present the side effects of these steroids (e.g., worsening of herpetic keratitis).

Lens and Eye Toxicity Research

Use of a specular microscope with pachymeter in ocular tolerance studies of eye drops in the rabbit

Author: Driot, J. Y. ; Decrouez, E. ; Bonne, C. ; Santoul, C.

Eye drops, unlike cosmetic or chems., only cause minor irritations which often prove difficult to objectively observe and assess.A specular microscope with pachymeter is used to measure corneal thickness, and to examine and photograph corneal endothelium in ocular tolerance studies in the rabbit.Rabbits were instilled 5 times a day for 16 days with BKC aqueous solution, 0.01% or 0.1% and subjected after anasthesia to 4 corneal inspections (before treatment, 7th and 14th days of treatment, 5th day after treatment).Only the 0.1% concentration provoked an increase in corneal thickness.Thickening progressed during the treatment period (5.3% on day 7, 26% on day 14) and strongly regressed 5 days after treatment stopped (3%).A slit lamp examination revealed very light or light corneal opacities, but the correlation between corneal thickening ratio and opacity was poor (r = 0,62).

100 Deals associated with Laboratoire Chauvin SAS

Login to view more data

100 Translational Medicine associated with Laboratoire Chauvin SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data